Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Open Text Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.5 (market cap $8.04B), while Open Text Corporation trades at $22.68 (market cap $5.40B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Open Text Corporation pays a 4.9% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | OTEX | |
|---|---|---|
Market Cap | $8.04B | $5.40B |
Sector | Health | Technology |
52-Week High | $339.75 | $39.69 |
52-Week Low | $241.71 | $20.01 |
Enterprise Value | $7.85B | $10.56B |
Dividend Yield | — | 4.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
OpenText (OTEX) trades at $23.57, up 2.43% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 73.06% gross margin and has beaten earnings estimates for the last three quarters. Recent strategic moves include a $105 million investment in European AI and cloud expansion and the divestiture of the non-core Vertica business.
The outlook is positive, supported by a consensus analyst price target of $29.75, implying significant upside. Key opportunities include margin expansion and AI-driven growth, while risks involve integration of strategic shifts and competitive pressures in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
